Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Lexaria Bioscience stock

Learn how to easily invest in Lexaria Bioscience stock.

Lexaria Bioscience, a Kelowna, Canada-based company that develops drug delivery platforms, is seeking a listing on the Nasdaq. The company is currently listed on the Over-the-Counter Markets under the ticker "LXRP," as well as the Canadian Securities Exchange under the ticker symbol "LXX."

How to buy shares in Lexaria Bioscience

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LEXX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Lexaria Bioscience stock price (NASDAQ: LEXX)

Use our graph to track the performance of LEXX stocks over time.

Lexaria Bioscience shares at a glance

Information last updated 2022-09-25.
Latest market close$2.45
52-week range$1.85 - $7.15
50-day moving average $2.89
200-day moving average $3.23
Wall St. target price$15.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.29

Buy Lexaria Bioscience shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Lexaria Bioscience stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lexaria Bioscience price performance over time

Historical closes compared with the close of $2.45 from 2022-09-30

1 week (2022-09-23) -0.81%
1 month (2022-09-02) -17.92%
3 months (2022-07-01) -11.23%
6 months (2022-03-29) N/A
1 year (2021-10-01) -61.60%
2 years (2020-10-02) 880.00%
3 years (2019-10-02) 483.33%
5 years (2017-10-02) 456.82%

Lexaria Bioscience financials

Revenue TTM $175,268
Gross profit TTM $547,392
Return on assets TTM -45.55%
Return on equity TTM -74.8%
Profit margin 0%
Book value $1.54
Market capitalisation $14.7 million

TTM: trailing 12 months

Lexaria Bioscience share dividends

We're not expecting Lexaria Bioscience to pay a dividend over the next 12 months.

You may also wish to consider:

Have Lexaria Bioscience's shares ever split?

Lexaria Bioscience's shares were split on a 1:30 basis on 12 January 2021. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lexaria Bioscience shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Lexaria Bioscience shares which in turn could have impacted Lexaria Bioscience's share price.

Lexaria Bioscience share price volatility

Over the last 12 months, Lexaria Bioscience's shares have ranged in value from as little as $1.85 up to $7.15. A popular way to gauge a stock's volatility is its "beta".

LEXX.US volatility(beta: 1.16)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lexaria Bioscience's is 1.1578. This would suggest that Lexaria Bioscience's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

To put Lexaria Bioscience's beta into context you can compare it against those of similar companies.

Lexaria Bioscience overview

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp.

Frequently asked questions

What percentage of Lexaria Bioscience is owned by insiders or institutions?
Currently 17.814% of Lexaria Bioscience shares are held by insiders and 9.553% by institutions.
How many people work for Lexaria Bioscience?
Latest data suggests 6 work at Lexaria Bioscience.
When does the fiscal year end for Lexaria Bioscience?
Lexaria Bioscience's fiscal year ends in August.
Where is Lexaria Bioscience based?
Lexaria Bioscience's address is: 100 ? 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7
What is Lexaria Bioscience's ISIN number?
Lexaria Bioscience's international securities identification number is: US52886N4060

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site